Dr Reddy's subsidiary inks pact with US-based Olema Pharmaceuticals

Dr Reddy's Laboratories on Thursday said its subsidiary has inked a pact with US-based Olema Pharmaceuticals Inc to research, develop and commercialise novel small molecule inhibitors of a target

Dr Reddy's, Labs
Dr Reddy’s, Labs
Press Trust of India New Delhi
2 min read Last Updated : Jun 09 2022 | 10:07 PM IST

Dr Reddy's Laboratories on Thursday said its subsidiary has inked a pact with US-based Olema Pharmaceuticals Inc to research, develop and commercialise novel small molecule inhibitors of an undisclosed oncology target.

Olema and Aurigene Discovery Technologies, a wholly-owned unit of Dr Reddy's Laboratories, have inked an exclusive global licence agreement in this regard.

Under the terms of the agreement, Olema will make an upfront licensing payment of USD 8 million for the rights to a pre-existing Aurigene programme.

Aurigene will also be eligible for up to USD 60 million in potential clinical development and regulatory milestones and up to USD 370 million in potential commercial milestones, as well as royalties ranging from the mid-single digits to the low double digits, based on annual net sales.

During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts, Dr Reddy's said in a regulatory filing.

Olema and Aurigene will jointly direct further preclinical work and, if successful, Olema will lead clinical development along with regulatory and commercial activities, it added.

"This agreement with Olema further validates Aurigene's proven expertise in discovery and preclinical development of effective cancer therapeutics," Aurigene CEO Murali Ramachandra said.

The company looks forward to the continued development of an Aurigene programme, which will now be ably supported by the extensive development capability of Olema, he added.

"We believe this is a strong strategic opportunity to enhance our growing discovery portfolio," said Sean P Bohen, President and Chief Executive Officer of Olema Oncology.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Dr Reddy's Laboratories LimitedDr ReddysDr Reddy's Labs

First Published: Jun 09 2022 | 10:06 PM IST

Next Story